BBP 454
Alternative Names: BBP-454Latest Information Update: 09 May 2024
At a glance
- Originator University of California at San Francisco
- Developer BridgeBio Oncology Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer